Prediction of progression of interstitial lung disease in patients with systemic sclerosis: The SPAR model

Annals of the Rheumatic Diseases

Volumn 77, Issue 9, 2018, Pages 1326-1332

  Wu, Wanlong ^a,b   Jordan, Suzana ^a   Becker, Mike Oliver ^a   Dobrota, Rucsandra ^a   Maurer, Britta ^a   Fretheim, Håvard ^c   Ye, Shuang ^b   Siegert, Elise ^d   Allanore, Yannick ^e   Hoffmann Vold, Anna Maria ^c   Distler, Oliver ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e université Paris Cité   (France)

Author keywords

arthritis; pulmonary fibrosis; systemic sclerosis

Indexed keywords

CARBON MONOXIDE; IMMUNOSUPPRESSIVE AGENT; OXYGEN;

ADULT; ARTHRITIS; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSESSMENT; DISEASE COURSE; DISEASE DURATION; FEMALE; FOLLOW UP; FORCED VITAL CAPACITY; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL LUNG DISEASE; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SIX MINUTE WALK TEST; SYSTEMIC SCLEROSIS; AGED; BLOOD; CLINICAL TRIAL; COMPLICATION; DIAGNOSTIC IMAGING; DISEASE EXACERBATION; EXERCISE TEST; LUNG DIFFUSION CAPACITY; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; PROSPECTIVE STUDY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; VITAL CAPACITY; X-RAY COMPUTED TOMOGRAPHY;

ADULT; AGED; DISEASE PROGRESSION; EXERCISE TEST; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; OXYGEN; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; PULMONARY DIFFUSING CAPACITY; RESPIRATORY FUNCTION TESTS; RISK ASSESSMENT; ROC CURVE; SCLERODERMA, SYSTEMIC; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; VITAL CAPACITY;

EID: 85048222865     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2018-213201     Document Type: Article

References (33)

1. D enton CP, Khanna D. Systemic sclerosis. Lancet 2017;390:1685-99.
2. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007;66:940-4.
3. Walker UA, Tyndall A, Czirják L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: A report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 2007;66:754-63.
4. Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 2017;76:1327-39.
5. T ashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655-66.
6. T ashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): A randomised controlled, double-blind, parallel group trial. Lancet Respir Med 2016;4:708-19.
7. Avouac J, Walker UA, Hachulla E, et al. Joint and tendon involvement predict disease progression in systemic sclerosis: A EUSTAR prospective study. Ann Rheum Dis 2016;75:103-9.
8. N ihtyanova SI, Schreiber BE, Ong VH, et al. Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheumatol 2014;66:1625-35.
9. Gilson M, Zerkak D, Wipff J, et al. Prognostic factors for lung function in systemic sclerosis: prospective study of 105 cases. Eur Respir J 2010;35:112-7.
10. Assassi S, Sharif R, Lasky RE, et al. Predictors of interstitial lung disease in early systemic sclerosis: A prospective longitudinal study of the GENISOS cohort. Arthritis Res Ther 2010;12:R166.
11. Cottrell TR, Wise RA, Wigley FM, et al. The degree of skin involvement identifies distinct lung disease outcomes and survival in systemic sclerosis. Ann Rheum Dis 2014;73:1060-6.
12. Hoffmann-Vold AM, Aaløkken TM, Lund MB, et al. Predictive value of serial highresolution computed tomography analyses and concurrent lung function tests in systemic sclerosis. Arthritis Rheumatol 2015;67:2205-12.
13. P lastiras SC, Karadimitrakis SP, Ziakas PD, et al. Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline. Arthritis Rheum 2006;55:598-602.
14. Moore OA, Goh N, Corte T, et al. Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease. Rheumatology 2013;52:155-60.
15. Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: A simple staging system. Am J Respir Crit Care Med 2008;177:1248-54.
16. Hax V, Bredemeier M, Didonet Moro AL, et al. Clinical algorithms for the diagnosis and prognosis of interstitial lung disease in systemic sclerosis. Semin Arthritis Rheum 2017;47:228-34.
17. O kamoto M, Fujimoto K, Sadohara J, et al. A retrospective cohort study of outcome in systemic sclerosis-associated interstitial lung disease. Respir Investig 2016;54:445-53.
18. Morisset J, Vittinghoff E, Elicker BM, et al. Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model. Chest 2017;152:999-1007.
19. R yerson CJ, O'Connor D, Dunne JV, et al. Predicting Mortality in Systemic Sclerosis-Associated Interstitial Lung Disease Using Risk Prediction Models Derived From Idiopathic Pulmonary Fibrosis. Chest 2015;148:1268-75.
20. Moore OA, Proudman SM, Goh N, et al. Quantifying change in pulmonary function as a prognostic marker in systemic sclerosis-related interstitial lung disease. Clin Exp Rheumatol 2015;33(4 Suppl 91):S111-6.
21. Goh NS, Hoyles RK, Denton CP, et al. Short-Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis. Arthritis Rheumatol 2017;69:1670-8.
22. Swigris JJ, Zhou X, Wamboldt FS, et al. Exercise peripheral oxygen saturation (SpO2) accurately reflects arterial oxygen saturation (SaO2) and predicts mortality in systemic sclerosis. Thorax 2009;64:626-30.
23. Winstone TA, Assayag D, Wilcox PG, et al. Predictors of mortality and progression in scleroderma-associated interstitial lung disease: A systematic review. Chest 2014;146:422-36.
24. Suliman YA, Dobrota R, Huscher D, et al. Brief Report: Pulmonary Function Tests: High Rate of False-Negative Results in the Early Detection and Screening of Scleroderma-Related Interstitial Lung Disease. Arthritis Rheumatol 2015;67:3256-61.
25. Khanna D, Distler JHW, Sandner P, et al. Emerging strategies for treatment of systemic sclerosis. J Scleroderma Relat Disord 2016;1:186-93.
26. van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: An American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis 2013;72:1747-55.
27. Frauenfelder T, Winklehner A, Nguyen TD, et al. Screening for interstitial lung disease in systemic sclerosis: performance of high-resolution CT with limited number of slices: A prospective study. Ann Rheum Dis 2014;73:2069-73.
28. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000;161(2 Pt 1):646-64.
29. P anopoulos ST, Bournia VK, Trakada G, et al. Mycophenolate versus cyclophosphamide for progressive interstitial lung disease associated with systemic sclerosis: A 2-year case control study. Lung 2013;191:483-9.
30. Wanchu A, Suryanaryana BS, Sharma S, et al. High-dose prednisolone and bolus cyclophosphamide in interstitial lung disease associated with systemic sclerosis: A prospective open study. Int J Rheum Dis 2009;12:239-42.
31. Hoyles RK, Ellis RW, Wellsbury J, et al. A multicenter, prospective, randomized, doubleblind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006;54:3962-70.
32. Wilsher M, Good N, Hopkins R, et al. The six-minute walk test using forehead oximetry is reliable in the assessment of scleroderma lung disease. Respirology 2012;17:647-52.
33. Valentini G, D'Angelo S, Della Rossa A, et al. European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. IV. Assessment of skin thickening by modified Rodnan skin score. Ann Rheum Dis 2003;62:904-5.